Cowen and Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-5,349
Closed -$385K 581
2022
Q4
$385K Sell
5,349
-8,710
-62% -$657K 0.04% 141
2022
Q3
$999K Buy
14,059
+9,005
+178% +$653K 0.1% 81
2022
Q2
$389K Sell
5,054
-9,621
-66% -$733K 0.04% 165
2022
Q1
$1.07M Buy
14,675
+4,767
+48% +$320K 0.1% 103
2021
Q4
$618K Sell
9,908
-26,405
-73% -$1.55M 0.06% 200
2021
Q3
$2.15M Buy
+36,313
New +$2.39M 0.1% 88
2020
Q1
Sell
-100
Closed -$6K 427
2019
Q4
$6K Buy
+100
New +$5.73K ﹤0.01% 407

Other funds holding BMY

Cowen and Company's BMY Position: Q1 2023 in Review

Cowen and Company sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 5,349 shares — an estimated $385K sold.

Cowen and Company first reported a position in BMY in Q4 2019 and held it in 7 quarters. The position peaked at $2.15M in Q3 2021. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

  • Cowen and Company reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 5,349 Bristol-Myers Squibb shares in Q1 2023, an estimated $385K.
  • Cowen and Company first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 7 quarters.
  • Cowen and Company's Bristol-Myers Squibb position peaked at $2.15M in Q3 2021.
  • 2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.